For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Research and development | 16,484 | 16,245* | 21,968 | 37,125 |
| General and administrative | 4,665 | 5,192* | 4,545 | 4,625 |
| Total operating expenses | 21,149 | 21,437 | 26,513 | 41,750 |
| Loss from operations | -21,149 | -21,437* | -26,513 | -41,750 |
| Interest income | 1,064 | 1,966* | 1,639 | 2,015 |
| Interest expense | 1,069 | 1,053* | 1,068 | 1,046 |
| Change in fair value of embedded derivatives | 460 | 260* | -440 | -40 |
| Other expense, net | -43 | 31* | -69 | -129 |
| Total other income | 412 | 1,204* | 62 | 800 |
| Net loss | -20,737 | -20,233* | -26,451 | -40,950 |
| Unrealized (gain) loss on marketable securities | -62 | -10* | 86 | 8 |
| Comprehensive loss | -20,799 | -20,243 | -26,365 | -40,942 |
| Basic EPS | -0.33 | -0.334 | -0.44 | -0.68 |
| Diluted EPS | -0.33 | -0.334 | -0.44 | -0.68 |
| Basic Average Shares | 63,219,289 | 60,538,658 | 60,573,425 | 60,573,425 |
| Diluted Average Shares | 63,219,289 | 60,538,658 | 60,573,425 | 60,573,425 |
Acumen Pharmaceuticals, Inc. (ABOS)
Acumen Pharmaceuticals, Inc. (ABOS)